Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia

(2009) John M. Kane et al.   AMERICAN JOURNAL OF PSYCHIATRY

Standards of Medical Care in Diabetes--2010

(2009)   DIABETES CARE

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

(2009) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia

(2009) John Lauriello et al.   JOURNAL OF CLINICAL PSYCHIATRY

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?

(2009) Viktoria Simon et al.   JOURNAL OF CLINICAL PSYCHIATRY

Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder

(2009) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia

(2009) Leslie Citrome et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY